498 related articles for article (PubMed ID: 17609264)
21. Dysregulation of Dual-Specificity Phosphatases by Epstein-Barr Virus LMP1 and Its Impact on Lymphoblastoid Cell Line Survival.
Lin KM; Lin SJ; Lin JH; Lin PY; Teng PL; Wu HE; Yeh TH; Wang YP; Chen MR; Tsai CH
J Virol; 2020 Jan; 94(4):. PubMed ID: 31776277
[TBL] [Abstract][Full Text] [Related]
22. Epstein-Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival.
Zimber-Strobl U; Kempkes B; Marschall G; Zeidler R; Van Kooten C; Banchereau J; Bornkamm GW; Hammerschmidt W
EMBO J; 1996 Dec; 15(24):7070-8. PubMed ID: 9003782
[TBL] [Abstract][Full Text] [Related]
23. The Ubiquitin Sensor and Adaptor Protein p62 Mediates Signal Transduction of a Viral Oncogenic Pathway.
Wang L; Howell MEA; Sparks-Wallace A; Zhao J; Hensley CR; Nicksic CA; Horne SR; Mohr KB; Moorman JP; Yao ZQ; Ning S
mBio; 2021 Oct; 12(5):e0109721. PubMed ID: 34488443
[TBL] [Abstract][Full Text] [Related]
24. PY motifs of Epstein-Barr virus LMP2A regulate protein stability and phosphorylation of LMP2A-associated proteins.
Ikeda M; Ikeda A; Longnecker R
J Virol; 2001 Jun; 75(12):5711-8. PubMed ID: 11356981
[TBL] [Abstract][Full Text] [Related]
25. The A20 deubiquitinase activity negatively regulates LMP1 activation of IRF7.
Ning S; Pagano JS
J Virol; 2010 Jun; 84(12):6130-8. PubMed ID: 20392859
[TBL] [Abstract][Full Text] [Related]
26. Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program.
De Leo A; Arena G; Stecca C; Raciti M; Mattia E
Mol Cancer Res; 2011 Oct; 9(10):1346-55. PubMed ID: 21856773
[TBL] [Abstract][Full Text] [Related]
27. The Epstein-Barr virus (EBV)-induced tumor suppressor microRNA MiR-34a is growth promoting in EBV-infected B cells.
Forte E; Salinas RE; Chang C; Zhou T; Linnstaedt SD; Gottwein E; Jacobs C; Jima D; Li QJ; Dave SS; Luftig MA
J Virol; 2012 Jun; 86(12):6889-98. PubMed ID: 22496226
[TBL] [Abstract][Full Text] [Related]
28. Interferon regulatory factor 7: a key cellular mediator of LMP-1 in EBV latency and transformation.
Zhang L; Pagano JS
Semin Cancer Biol; 2001 Dec; 11(6):445-53. PubMed ID: 11669606
[TBL] [Abstract][Full Text] [Related]
29. A novel dominant-negative mutant form of Epstein-Barr virus latent membrane protein-1 (LMP1) selectively and differentially impairs LMP1 and TNF signaling pathways.
Adriaenssens E; Mougel A; Goormachtigh G; Loing E; Fafeur V; Auriault C; Coll J
Oncogene; 2004 Apr; 23(15):2681-93. PubMed ID: 14767477
[TBL] [Abstract][Full Text] [Related]
30. Induction of latent membrane protein expression in in vitro Epstein-Barr virus-infected leukaemic B lymphocytes by interleukin 4 and antibodies to CD40.
Crawford DH; Thomas JA; Gregory CD; Catovsky D; Chaggar K
Leukemia; 1995 May; 9(5):747-53. PubMed ID: 7539512
[TBL] [Abstract][Full Text] [Related]
31. Epstein-Barr virus: exploiting the immune system.
Thorley-Lawson DA
Nat Rev Immunol; 2001 Oct; 1(1):75-82. PubMed ID: 11905817
[TBL] [Abstract][Full Text] [Related]
32. Tyrosines 60, 64, and 101 of Epstein-Barr virus LMP2A are not essential for blocking B cell signal transduction.
Swart R; Fruehling S; Longnecker R
Virology; 1999 Oct; 263(2):485-95. PubMed ID: 10544120
[TBL] [Abstract][Full Text] [Related]
33. Colocalization of interferon regulatory factor 7 (IRF7) with latent membrane protein 1 (LMP1) of Epstein-Barr virus.
Kim IW; Park HS
J Korean Med Sci; 2006 Jun; 21(3):379-84. PubMed ID: 16778376
[TBL] [Abstract][Full Text] [Related]
34. Identification of rare Epstein-Barr virus infected memory B cells and plasma cells in non-monomorphic post-transplant lymphoproliferative disorders and the signature of viral signaling.
Shaknovich R; Basso K; Bhagat G; Mansukhani M; Hatzivassiliou G; Murty VV; Buettner M; Niedobitek G; Alobeid B; Cattoretti G
Haematologica; 2006 Oct; 91(10):1313-20. PubMed ID: 17018379
[TBL] [Abstract][Full Text] [Related]
35. Role of latent membrane protein 2 isoforms in Epstein-Barr virus latency.
Rechsteiner MP; Bernasconi M; Berger C; Nadal D
Trends Microbiol; 2008 Nov; 16(11):520-7. PubMed ID: 18835714
[TBL] [Abstract][Full Text] [Related]
36. Expression of the simian Epstein-Barr virus-encoded latent membrane protein-1 in malignant lymphomas of SIV-infected rhesus macaques.
Blaschke S; Hannig H; Buske C; Kaup FJ; Hunsmann G; Bodemer W
J Med Virol; 2001 Sep; 65(1):114-20. PubMed ID: 11505452
[TBL] [Abstract][Full Text] [Related]
37. Multiple roles of LMP1 in Epstein-Barr virus induced immune escape.
Middeldorp JM; Pegtel DM
Semin Cancer Biol; 2008 Dec; 18(6):388-96. PubMed ID: 19013244
[TBL] [Abstract][Full Text] [Related]
38. c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells.
Faumont N; Durand-Panteix S; Schlee M; Grömminger S; Schuhmacher M; Hölzel M; Laux G; Mailhammer R; Rosenwald A; Staudt LM; Bornkamm GW; Feuillard J
J Virol; 2009 May; 83(10):5014-27. PubMed ID: 19264782
[TBL] [Abstract][Full Text] [Related]
39. Oncogenic IRFs provide a survival advantage for Epstein-Barr virus- or human T-cell leukemia virus type 1-transformed cells through induction of BIC expression.
Wang L; Toomey NL; Diaz LA; Walker G; Ramos JC; Barber GN; Ning S
J Virol; 2011 Aug; 85(16):8328-37. PubMed ID: 21680528
[TBL] [Abstract][Full Text] [Related]
40. An Epstein-Barr Virus MicroRNA Blocks Interleukin-1 (IL-1) Signaling by Targeting IL-1 Receptor 1.
Skinner CM; Ivanov NS; Barr SA; Chen Y; Skalsky RL
J Virol; 2017 Nov; 91(21):. PubMed ID: 28794034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
